ERBB2 and neoplasm: HER3 upregulation has been related to trastuzumab resistance in studies [19, 106] showing that breast cancers driven primarily by HER2 homodimerization are more susceptible to trastuzumab therapy than tumours with a predominance of HER2-HER3 heterodimers.